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A B S T R A C T
Aim of our study was to determine the treatment habits of hypertension by general practitioners (GPs) as well as the
monthly costs of prescribed antihypertensive drugs and their share in the total prescription drug expenditure approved
by the Croatian Institute for Health Insurance (CIHI), the compulsory health insurance system. The study was per-
formed in six GPs offices in Zagreb, serving 8,866 patients, in December 2005. The monthly costs of antihypertensive
drugs prescribed by the GPs was obtained by summarizing the prices of all antihypertensive drugs prescribed in one
month and then comparing the sum with total monthly prescription drug expenditure approved by the CIHI. The type
and dosage of prescribed antihypertensive drugs were also analyzed. Hypertension was diagnosed in 2,342 (26.4%) pa-
tients. The monthly costs of prescribed antihypertensive drugs accounted for 52.33% of the total amount approved for
medications by the CIHI. 945 (40.0%) hypertensive patients were taking antihypertensive monotherapy. The most fre-
quently prescribed drugs as monotherapy were ACE inhibitors (38.3%), calcium-channel blockers (26.7%), b blockers
(18.6%), and diuretics (10.3%). a antagonists (3.6%). Angiotensin receptor blockers (2.5%) were rarely prescribed. As
combination therapy, ACE inhibitors and diuretics (30.4%) were most frequently used. More than 50% of the funds allo-
cated to GPs for medications were spent for the treatment of only one disease. The most used antihypertensive drugs were
ACE inhibitors.
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Introduction
Hypertension is the main risk factor for cerebro-
vascular diseases and one of the main risk factor for car-
diovascular diseases (CVD). These diseases are the lead-
ing cause of death in Europe, an important cause of
disability and a big economic burden for any country. De-
spite abundant long-standing knowledge about hyper-
tension and its diagnostics, treatment and consequences,
hypertension is still poorly treated. In the year 2000, 927
million (26.4%) of the world population suffered from hy-
pertension. The World Health Organization (WHO) esti-
mates that there are 11% of undetected hypertensive pa-
tients in the developed world and 50% in the developing
countries. At the same time only 34% of hypertensive pa-
tients are treated properly and are achieving recom-
mended targets of blood pressure. By the year 2025, the
number of hypertensive patients will rise by 60%, which
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will seriously drain economic resources1. In 2003 the
prevalence of hypertension in Europe was 44.2% (Ger-
many 55%, Finland 49%, Spain 47%, Sweden and Italy
38%)1. In the same year, The Seventh Report of the Joint
National Committee on Prevention, Evaluation and
Treatment of High Blood Pressure2 and the European
Society of Hypertension – European Society of Cardiol-
ogy (ESH/ESC)3 together with World Organization of
National Colleges, Academies and Academic Associations
of General Practitioners/Family Physicians (WONCA)4
produced new guidelines in 2007 for early diagnosis and
proper management of arterial hypertension. The objec-
tives of these guidelines were to help health professionals
to reduce the occurrence of CVD through modifications
of cardiovascular risk factors, and to encourage each
country to find their own pathway.
The prevalence of hypertension in Croatia is 37.5%,
which is similar to Italy and Sweden5. Many hyperten-
sive patients in Croatia still remain undetected, but it is
very important to stress that CVD are killer number one
in Croatia, being responsible for 53% of all deaths6.
The diagnosis of patients with hypertension at an
early age increases the expenditure for their treatment.
However, studies show that the expenditure for early
treatment of hypertension is still lower than the costs of
treatment of untreated or improperly treated hyperten-
sion consequences7,8. According to European cardiovas-
cular disease statistics, in 2005 the costs of inpatient hos-
pital care for cardiovascular patients accounted for about
57% of all costs, and the costs of drugs accounted for
about 27%9. In Croatia, like in many other countries, the
costs of medication are constantly growing. In 2003,
21.3% of Croatian health budget was spent on drugs
(17.4% more than in 2002)10. For medical treatment of
only three diseases (hypertension, hypercholesterolemia,
and diabetes mellitus) in 2005 was spent 81.2% of total
prescription drugs expenditure approved by CIHI11. In
Italy, annual increase of medication costs is 11%, and in
the USA it is 22.8%12,13. In most countries, the use of
antihypertensive drugs has increased by 60% for the last
five years14.
Every year, the Croatian Institute for Health Insur-
ance (CIHI), the national compulsory health insurance
system, determines the amount of money that GPs are
allowed to spend on prescription drugs, and that amount
depends on the budget allocated for the primary health
care. GPs, as independent contractors with the CIHI,
sign an annual contract that stipulates the approved
amount15 and obliges them to keep the expenses of pre-
scription drugs within these limits. If they overspend
without justification, the CIHI first sends an official
warning, then imposes a financial penalty, and eventu-
ally cancels their contract16. So, the GPs in Croatia are in
an inconvenient situation, if they detected and treated
their hypertensive patients according to guidelines they
would spend the high amount of money and would be
punished. The CIHI should be aware of growing costs of
drugs and allocate a higher amount of money for pre-
scribed medications.
Our aim was to determine the prevalence of hyperten-
sion in family medicine in an urban area (city of Zagreb)
and to calculate monthly costs of antihypertensive drugs,
as well as to determine their share in the total prescrip-
tion drug budget allocated to GPs by the CIHI. We also
wanted to investigate the type and the number of pre-
scribed antihypertensive drugs per one patient.
Participants and Methods
The retrospective study was performed in six GP of-
fices in Zagreb, serving 8,866 patients, in December
(01.12. to 31.12.) 2005. All six offices were equipped with
PCs and kept medical records in an electronic form.
Participants
A total of 8,866 patients were divided into 5 age
groups (0–34, 35–44, 45–54, 55–64 and  65 years of age),
according to which the CIHI allocates the budget for pre-
scription drugs.
The patients with hypertension were identified, and
the amount of money spent on the prescription drugs for
their treatment was recorded. Patients with blood pres-
sure 140/90 mm Hg at two consecutive measurements,
and patients who had normal blood pressure but were
taking antihypertensive drugs were considered to suffer
from hypertension2,3. The type and the number of pre-
scribed antihypertensive drugs were also examined.
Cost-analysis
Monthly expenditure for antihypertensive drugs was
obtained by the summation of monthly expenses on
antihypertensive drugs for each patient and then com-
pared with the total monthly prescription drug expendi-
ture approved to GPs by the CIHI according to the fol-
lowing formula: number of patients x approved drug
budget per one insured person in 2005/12 months.
Statistical Analysis
Differences between patient age groups and Croatian
population were tested by c² test. The statistical analysis
was performed with SPSS 9.0 software (SPSS Inc., Chi-
cago, IL, USA, 1999).
Results
The age distribution of patients included in the study
corresponds with the age distribution of the whole Cro-
atian population; 1,921 persons at the age 0 to 34; 1,507
at the age 35 to 44; 1,386 at the age 45 to 54; 1,295 at the
age 55 to 64; and 2,757 older than 65.
Hypertension was diagnosed in 2,342 (26.4%) out of
8,866 patients.
Hypertension was most frequently diagnosed in the
oldest group of patients, i.e., those aged over 65, not one
hypertensive patient was diagnosed in the age group
0–34 years of age. The incidence of the diagnosed hyper-
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tension was lowest in patients between 35 an 44 years of
age, and increased with age (Table 1).
The prescription drug expenses per insured person
approved by the Croatian Institute for Health Insurance
in 2005 increased with age. The monthly amount that
the six GPs spent on investigated prescription of antihy-
pertensive drugs for the patients included in this study
was 32 080.93€ or 52.33% of the total amount approved
by the CIHI, which was 61 299.30€ for one month. The
highest expenditure for the investigated drugs were found
in the oldest group of patients (aged 65). The prescrip-
tion drug expenses rise from 16.2% to 64.6% according to
age groups. The correlation between these two variables
is high (r=0.998) (Table 2).
The prescription habits of GPs including antihyper-
tensive monotherapy or combination therapy for hyper-
tensive patients did not depend on patients age (c=6.581,
df=3, p=0.087). The GPs equally prescribed monothe-
rapy and polytherapy to the youngest group of patients
as well as to the oldest (Table 3).
The most frequent drugs used as monotherapy were
ACE inhibitors in all age groups followed by calcium
channel blockers in older age groups (55 and older). In
the youngest group of hypertensive patients the most
prescribed antihypertensive drugs were b blockers. The
AR antagonist were most frequently prescribed to age
group from 55 to 64. The kind and frequency of pre-
scribed antihypertensive drugs according to age groups
of patients taking monotherapy is shown on Table 4.
1 245 (53.2%) of patients with arterial high blood
pressure were treated with a combination of two anti-
hypertensive drugs. The combination of two prescribed
antihypertensive drugs was the highest in the age group
older than 65 and in the age group from 45 to 54. The
most offten prescribed combination of antihypertensive
drugs was ACE inhibitors with diuretics in all age groups.
Other drugs combinations were prescribed equally (Ta-
ble 5).
152 (6.4%) hypertensive patients were prescribed a
combination of three and more antihypertensive drugs
by the GPs.
Discussion
We found that the expenditure for antihypertensive
drugs for all age groups of patients amounted to 52.3% of
the total amount allocated by the Croatian Institute for
Health Insurance (CIHI) to the GPs for prescription
drugs in 2005. Antihypertensive drugs in Croatia ac-
counted for more than half of the prescription drug ex-
penditure in this study like in the similar study a few
years ago17, although only 22.6% of patients had diag-
nosed hypertension and the prevalence of hypertension
in Croatia is 37.5%5. In the USA, antihypertensive drugs
for 27.8% of all patients with hypertension accounted for
45% of drug expenditure18. So, it was shown from the
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TABLE 1
DISTRIBUTION OF PATIENTS WITH HYPERTENSION
ACCORDING TO AGE GROUPS
Age group No. (%) of patients
No. of patients with
hypertension (%)
0–34 1921 (21.66) 0 (0.0)
35–44 1507 (16.99) 82 (5.44)
45–54 1386 (15.63) 200 (14.43)
55–64 1295 (14.60) 457 (35.29)
 65 2575 (29.04) 1603 (58.14)
Total 8866 (100.00) 2342 (26.40)
TABLE 2
EXPENDITURE FOR ANTIHYPERTENSIVE DRUGS IN COMPARISON WITH TOTAL PRESCRIPTION DRUGS EXPENDITURE AND
APPROVED DRUGS EXPENDITURE BY CROATIAN INSTITUTE FOR HEALTH INSURANCE IN 2005 ACCORDING TO AGE GROUPS
Age groups
(years)
No of.
patients
Approved drug expenditure per patient Monthly prescription drugs expenditure (€)
Year/month (€) Total (€) Spent on antihypertensive drugs € (%)
0–34 1921 130.79 / 10.89 2 842.35 0.00 (0.00)
35–44 1507 229.08 / 19.09 3 908.78 633.82 (16.22)
45–54 1386 434.49 / 36.90 6 817.01 2 384.52 (34.98)
55–64 1295 825.54 / 68.79 12 103.68 6 038.32 (49.89)
 65 2575 1141.30 / 95.11 35 627.48 23 024.27 (64.63)
Total 8866 61 299.30 32 080.93 (52.33)
TABLE 3
DISTRIBUTION OF PATIENTS WITH HYPERTENSION ON
MONOTHERAPY AND POLYTHERAPY ACCORDING TO AGE
GROUPS
Age
group
Total No. of
patients
No. of patients
on monotherapy
No. of patients
on polytherapy
0–34 0 0 0
35–44 81 44 37
45–54 188 81 107
55–64 434 199 235
65 1487 621 866
Total 2190 945 1245
(c=6.581, df=3, p=0.087)
data that GPs were spent more money for prescribed
antihypertensive drugs for fewer detected hypertensive
patients. The highest expenditure (64.6%) was in the old-
est age group (patients older than 65). This means that
only about 35% of the allowed total prescription drugs
budget is available for the treatment of all the other
chronic diseases. This is particularly worrying since most
of the hypertensive patients have at the same time hyper-
lipidemia, diabetes etc. The GPs, who diagnose and treat
hypertension more frequently, will induce higher drug
expenditure. The prevalence of diagnosed hypertension –
26.4% of all subjects in this study was almost half of the
European average (44.2% for those older than 35), and
the Croatian average as well (37.5%)5. Although differ-
ences in the prevalence of hypertension between differ-
ent European countries do exist1, Croatia is very similar
to Sweden and Italy19. Low prevalence of diagnosed hy-
pertension in this study could perhaps be explained by
the fact that GPs are not obliged and motivated to follow
professionals guidelines for the detection and treatment
of hypertension. If GPs followed the guidelines, it would
increase the number of patients with hypertension and
cause increased expenditure for prescription antihyper-
tensive drugs. Consequently, GPs who actively partici-
pate in diagnosing patients with hypertension, may, due
to exceeding the budget allocated for prescription drugs,
be penalized by the CIHI. Resources allocated by the
CIHI are obviously insufficient when more than 50% of
the budget is spent on the treatment of only one disease.
However, high expenditure for antihypertensive drugs is
a problem not only in Croatia, but in other European
countries, as well. Various programs to ensure low costs
and adequate treatments at the same time are being de-
signed.
Results of this study indicating that no cases of hyper-
tension were diagnosed in the age group 0–34, while only
12% were diagnosed in the age group 35–54, are worry-
ing. In the Netherlands, for example, 18.2% of hyperten-
sive patients were recorded in the age group 35–54 and it
was concluded that hypertension in this age group was
insufficiently diagnosed20. Numerous studies show that
aging is associated with an increased number of hyper-
tensive patients, 70% of them being older than 6521. Al-
though in our study in this age group the prevalence of
diagnosed hypertension was highest (58.1%), most of
them, probably, still remained undetected.
According to new guidelines, when GPs choose a type
of antihypertensive drug for their patient, they should
consider patients total cardiovascular risk factors and
subclinical organs damage3,4. Also, numerous studies show
that for achieving of recommended blood pressure tar-
gets, many more hypertensive patients should take two
or more antihypertensives22–24. Results of our study show
that 43.1% were taking one antihypertensive drug which
is a lot. The most frequently prescribed drugs as mono-
therapy in our study were ACE inhibitors. Similar re-
sults were obtained by other surveys22–24. Only 10.3% of
our patients with hypertension were taking diuretics, as
compared with the USA where 38% patients on mono-
therapy are taking diuretics, and only 32% ACE inhibi-
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TABLE 4
THE KIND OF ANTIHYPERTENSIVE DRUGS AS MONOTHERAPY ACCORDING TO AGE GROUPS.(N-945)
Age group No. Diuretics ACE inhibitors
Antihypertensive drugs (% of patients)
b blockers Calcium- channel blockers a blockers Antagonists AR
0–34 0 0.0 0.0 0.0 0.0 0.0 0.0
35–44 44 7.4 27.3 45.5 9.1 2.3 2.27
45–54 81 8.5 40.7 33.3 13.6 2.5 2.47
55–64 199 8.5 32.2 23.6 28.1 2.0 5.52
65 621 0.9 40.7 13.2 29.1 4.4 1.61
Total 945 10.2 38.3 18.6 26.7 3.6 2.54
TABLE 5
THE MOST FREQUENT DUAL COMBINATIONS OF ANTIHYPERTENSIVE DRUGS ACCORDING TO AGE GROUPS (N=1245)
Age
group
No. (%) of
patients
Antihypertensive drugs (% of patients) Ca-channel
blockers
+ diuretic
ACE inhib.
+ diuretics
ACE inhib + Ca-channel
blockers
ACE inhib
+ b blok
Ca-channel blockers
+ b blok
0–34 0.0 0.0 0.0 0.0 0.0 0.0
35–44 37 (45.1) 13.5 5.4 16.2 10.8 5.4
45–54 107 (53.5) 23.4 15.9 18.7 16.8 4.7
55–64 235 (51.4) 24.7 21.3 18.7 10.6 5.5
65 866 (54.0) 38.5 23.4 9.1 7.9 7.0
Total 1245 (53.2) 30.4 21.8 12.0 9.3 6.5
tors. In the UK 54% of patients are treated with diuretics
and b blockers25,26. The percentage of our patients on
monotherapy as well as of our patients on combination
therapy with two or more antihypertensive drugs was
similar to those in other studies24.
The main limitation of our study was that we did not
calculate a cost-benefit or cost-utility analysis for anti-
hypertensive treatment but only analysed global costs.
We also did not analyse in how many of hypertensive pa-
tients GPs achieved the recommended targets of hyper-
tension according to prescribed number and type of anti-
hypertensive drugs. Only urban population was included
in this study, so that conclusions could not be made gen-
erally for total drug expenditure of all GPs in whole
Croatia.
Having a lot of patients with hypertension in Croatia
undetected (the prevalence in Europe is higher and the
WHO estimates about 50% of undetected hypertensive
patients in the developing countries1), we can expect a
further increase of prescription antihypertensive drugs
expenditure. This significant economic burden has re-
sulted in designing numerous programs to reduce the
expenditure27.
Adequate education of GPs about the importance of
implementing guidelines in the diagnosing and treat-
ment of hypertension is most important. It has been
shown that only 40% of GPs implement these guidelines
in their everyday work and that proper application of the
guidelines in prescribing antihypertensive drugs might
save at least 11.6 million dollars28.
Numerous procedures have been designed and carried
out aiming at decreasing treatment costs for chronic
diseases29,30. Apart from GPs, specialists in hospitals
should also be warned against the adopted practice that
only 9.5% of hospital releases get prescribed generic
drugs and that they should take the price of drugs into
account as well31.
Conclusions
The expenditure for prescribed antihypertensive drugs
in Croatia amounted to more than 50% of the total
amount allocated by the Croatian Institute for Health In-
surance, the compulsory health insurance system. The
hypertension is not sufficiently diagnosed, especially in
younger age groups of patients. The GPs prescription
habits should be influenced by the recommended profes-
sional guidelines. The society and the health insurance
system should be aware of the trend in the whole world
that indicate the existence of an increased number of di-
agnosed hypertensive patients which is followed by in-
creased antihypertensive drugs expenditure. However, it
should be emphasized that, according to numerous stud-
ies, early diagnosis and proper treatment prevents the
consequences of hypertension and decrease the total bur-
den on the health budget.
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LIJE^ENJE HIPERTENZIJE OD STRANE LIJE^NIKA OBITELJSKE MEDICINE I POTRO[NJA ZA
ANTIHIPERTENZIVNE LIJEKOVE U GRADSKOJ SREDINI
S A @ E T A K
Cilj ovog istra`ivanja bio je ispitati navike lije~nika obiteljske medicine u lije~enju hipertenzije i izra~unati udio
mjese~ne potro{nje za antihipertenzivene lijekove u ukupnoj dozvoljenoj potro{nji za lijekove. Istra`ivanje je provedeno
na populaciji (N = 8.866) iz {est ordinacija obiteljske medicine u Zagrebu, lije~enih tijekom prosinca 2005. Mjese~na
potro{nja za antihipertenzivne lijekove propisane od strane lije~nika obiteljske medicine je uspore|ena sa dozvoljenom
ukupnom potro{njom za lijekove odobrene od strane Hrvatskog zavoda za zdravstveno osiguranje (HZZO). Analizirane
su tako|er vrsta i broj propisanih antihipertenzivnih lijekova svakom hipertoni~aru. Dijagnosticiranu hipertenziju imalo
je 26,4% promatrane populacije, a mjese~na potro{nja njima propisanih antihipertenzivnih lijekova iznosila je 52,33%
ukupno dozvoljene potro{nje za lijekove. Monoterapiju je koristilo 945 (40,0%) bolesnika. Najpropisivaniji antihiper-
tenzivni lijekovi u monoterapiji su bili ACE inhibitori (38,3%), blokatori kalcijskih kanala (26,7%), b blokeri (18,6%) i
diuretici (10,3%). a antagonisti (3,6%), blokatori angiotenzinskih receptoraand (2,5%) su rijetko propisivani. Naj~e{}e
kombinirani antihipertenzivi kod hipertoni~ara kojima su bila propisana dva antihipertenziva bili su ACE inhibitori i
diuretici (30,4%). Preko 50% dozvoljenih ukupnih sredstava za propisivanje lijekova lije~nicima obiteljske medicine
potro{eno je za samo jednu bolest. Naj~e{}e propisivan antihipertenzivni lijek je bio ACE inhibitor.
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